Biopharmaceutical company discovering and developing medicines for unmet medical needs.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company dedicated to advancing global healthcare by developing and acquiring innovative technologies that support pharmaceutical companies in their quest to discover and develop new medicines. The company's robust portfolio includes several commercial programs such as Kyprolis and Evomela, vital treatments for multiple myeloma, as well as Veklury, which addresses moderate to severe cases of COVID-19. Ligand also offers Teriparatide for osteoporosis, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine targeting pneumococcal pneumonia in children.
Ligand Pharmaceuticals is committed to enhancing therapeutic options across various medical domains. Its product lineup extends to Rylaze for acute lymphoblastic leukemia, Nexterone for cardiac arrhythmias, and Zulresso for postpartum depression, all developed using its proprietary captisol technology. The company also provides Noxafil-IV for invasive fungal infections, Duavee for postmenopausal osteoporosis, and a range of Aziyo products for pericardial repair and extracellular matrix applications.
Collaborating with partners globally, Ligand Pharmaceuticals expands its impact in clinical development, focusing on treatments for cancer, seizure disorders, diabetes, cardiovascular diseases, muscle wasting, liver and kidney ailments, and other critical conditions. Additionally, the company supplies Captisol materials, reinforcing its role as a key contributor to advanced drug formulation and delivery technologies.
Founded in 1987 and headquartered in San Diego, California, Ligand Pharmaceuticals continues to drive innovation and excellence in pharmaceutical development. Through strategic partnerships and ongoing research initiatives, Ligand remains dedicated to improving patient outcomes and addressing unmet medical needs worldwide.